Skip to main content
NCBI home page
California Medicine logoLink to California Medicine
. 1963 Apr;98(4):189–194.

HORMONAL TREATMENT OF DISSEMINATED CANCER OF THE FEMALE BREAST

Gilbert S Gordan, William P Graham III, Leon Goldman, Rose Papac, Glenn E Sheline, Jerome Vaeth, Joseph Witt
PMCID: PMC1575613  PMID: 13949172

Abstract

1. The University of California Medical Center at San Francisco is participating in a nationwide cooperative study attempting to improve hormonal therapy of disseminated breast cancer. A prospective protocol is followed in which the antitumor efficacy of an investigational compound is compared with that of a reference standard of known efficacy. Known variables (menopausal age and site of most significant metastasis) are randomized to distribute similar patients into experimental and control groups. Assignment of the therapeutic agent is made at random to avoid bias, and where feasible, neither patient nor investigator knows which compound is given.

2. Primary hormonal therapy of objectively progressing disseminated breast cancer yields objective regressions in approximately 22 percent of patients treated with any of the following: testosterone propionate, 2-alpha methyldihydrotestosterone propionate (a derivative which produces less virilization) and oral diethylstilbestrol. The average duration of regression is 10 months.

3. After primary hormonal therapy has ceased to be effective, secondary hormonal therapy produces fewer than 12 per cent objective regressions when conventional estrogens, androgens, corticoids, or surgical hypophysectomy are employed. The rate rises to 19-26 per cent if corticoids are combined with triiodothyronine, or if the less virilizing androgen, 2-alpha methyldihydrotestosterone propionate is used instead of other androgens. Surprisingly, hydrocortisone 30 mg. plus triiodothyronine 50 micrograms—an innocuous combination—proved as effective as doses producing Cushing's phenomena.

Full text

PDF
189

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BLACKBURN C. M., CHILDS D. S., Jr Use of 2 alpha-methyl androstan-17 beta-ol, 3-one (2-methyl dihydrotestosterone) in the treatment of advanced cancer of the breast. Proc Staff Meet Mayo Clin. 1959 Mar 4;34(5):113–126. [PubMed] [Google Scholar]
  2. DAO T. L., TAN E., BROOKS V. A comparative evaluation of adrenalectomy and cortisone in the treatment of advanced mammary carcinoma. Cancer. 1961 Nov-Dec;14:1259–1265. doi: 10.1002/1097-0142(196111/12)14:6<1259::aid-cncr2820140616>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
  3. GARDNER B., GORDAN G. S. Does urinary calcium excretion reflect growth or regression of disseminated breast cancer? J Clin Endocrinol Metab. 1962 Jun;22:627–630. doi: 10.1210/jcem-22-6-627. [DOI] [PubMed] [Google Scholar]
  4. GARDNER B., GORDAN G. S., LOKEN H. F., THOMAS A. N. Calcium and phosphate metabolism in disseminated breast cancer: effects of site, progression or regression, and hormonal treatment. Cancer Chemother Rep. 1962 Feb;16:299–303. [PubMed] [Google Scholar]
  5. GARDNER B., THOMAS A. N., GORDAN G. S. Antitumor efficacy of prednisone and sodium liothyronine in advanced breast cancer. Cancer. 1962 Mar-Apr;15:334–337. doi: 10.1002/1097-0142(196203/04)15:2<334::aid-cncr2820150216>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  6. GOLDENBERG I. S., BAILAR J. C., 3rd, HAYES M. A., LOWRY R. Female breast cancer: a re-evaluation. Ann Surg. 1961 Sep;154:397–404. doi: 10.1097/00000658-196109000-00009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. JESSIMAN A. G., MATSON D. D., MOORE F. D. Hypophysectomy in the treatment of breast cancer. N Engl J Med. 1959 Dec 10;261:1199–1207. doi: 10.1056/NEJM195912102612401. [DOI] [PubMed] [Google Scholar]
  8. LOWE R., DE LORIMIER A. A., Jr, GORDAN G. S., GOLDMAN L. Antitumor efficacy of fluoxymesterone. Use in advanced breast cancer. Arch Intern Med. 1961 Feb;107:241–244. doi: 10.1001/archinte.1961.03620020091008. [DOI] [PubMed] [Google Scholar]
  9. PEARSON O. H., RAY B. S. Hypophysectomy in the treatment of metastatic mammary cancer. Am J Surg. 1960 Apr;99:544–552. doi: 10.1016/0002-9610(60)90149-5. [DOI] [PubMed] [Google Scholar]
  10. SEGALOFF A., CARABASI R., HORWITT B. N., SCHLOSSER J. V., MURISON P. J. Hormonal therapy in cancer of the breast. VI. Effect of ACTH and cortisone on clinical course and hormonal excretion. Cancer. 1954 Mar;7(2):331–334. doi: 10.1002/1097-0142(195403)7:2<331::aid-cncr2820070218>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  11. SEGALOFF A., WEETH J. B., RONGONE E. L., MURISON P. J., BOWERS C. Y. Hormonal therapy in cancer of the breast 16. The effect of Delta 1-testololactone on clinical course and hormonal excretion. Cancer. 1960 Sep-Oct;13:1017–1020. doi: 10.1002/1097-0142(196009/10)13:5<1017::aid-cncr2820130523>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  12. STOLL B. A. Dexamethasone in advanced breast cancer. Cancer. 1960 Sep-Oct;13:1074–1080. doi: 10.1002/1097-0142(196009/10)13:5<1074::aid-cncr2820130531>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  13. THOMAS A. N., GORDAN G. S., GOLDMANL, LOWE R. Antitumor efficacy of 2alpha-methyl dihydrotestosterone propionate in advanced breast cancer. Cancer. 1962 Jan-Feb;15:176–178. doi: 10.1002/1097-0142(196201/02)15:1<176::aid-cncr2820150124>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]

Articles from California Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES